Aspect Biosystems Raises $115 Million Series B to Advance Bioprinted Tissue Therapeutics
Aspect Biosystems, a Vancouver-based biotechnology company, has secured $115 million in a Series B funding round to advance its bioprinted tissue therapeutics pipeline. The investment will help accelerate the company’s mission to develop next-generation cellular medicines for metabolic and endocrine diseases.
The funding round was led by Dimension, with participation from prominent investors including Novo Nordisk, Radical Ventures, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund. The strong support from both new and existing investors highlights the growing interest in regenerative medicine and Aspect’s innovative approach to bioprinted tissue therapeutics.
Aspect Biosystems is pioneering the development of bioprinted tissues that can be used as therapeutics for chronic diseases such as diabetes and liver disorders. The company’s proprietary microfluidic 3D bioprinting technology allows for the precise fabrication of functional tissues, offering new possibilities for disease treatment and transplantation.
The $115 million raised will be used to advance several therapeutic programs into clinical trials, with a focus on creating cellular therapies that offer long-lasting solutions for patients. Aspect also plans to expand its research and development capabilities and invest in its clinical manufacturing infrastructure to support the growing pipeline of bioprinted tissue products.
This financing follows a $200 million partnership with the Canadian and British Columbian governments, aimed at bolstering clinical biomanufacturing and advancing Aspect’s innovative therapies. The collaboration underscores the company’s strategic importance in the Canadian biotech ecosystem and its potential to drive significant medical breakthroughs.
Nan Li, Founder and Managing Partner at Dimension, will join Aspect Biosystems’ Board of Directors. Li praised Aspect’s multidisciplinary approach, combining bioengineering, cell biology, and advanced manufacturing to develop transformative therapies for complex diseases.
With the new funding, Aspect Biosystems is well-positioned to lead the development of bioprinted tissue therapeutics, offering hope to patients with chronic and life-threatening conditions. The company’s progress signals a promising future for regenerative medicine and the potential to reshape how we treat a wide range of diseases.
